Evidence map›Paper›PMID 31621674›Full record

Observational studyAnnals of cardiac anaesthesia

Adequacy of hemostatic resuscitation improves therapeutic efficacy of recombinant activated factor VII and reduces reexploration rate for bleeding in postoperative cardiac surgery patients with refractory hemorrhage.

Joel T Feih, Janelle J Juul, Joseph R G Rinka, Lisa M Baumann Kreuziger, Paul S Pagel, Justin N Tawil

Open access · diamondAbstract readObservational Study
In one paragraph

Observational study in Annals of cardiac anaesthesia. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.2field-weighted citation impact, top 57% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Joel T FeihDepartment of Pharmacy, Froedtert and the Medical College of Wisconsin; Department of Anesthesiology, Medical College of Wisconsin, Milwaukee, Wisconsin, USA.
Janelle J JuulDepartment of Pharmacy, Froedtert and the Medical College of Wisconsin, Milwaukee, Wisconsin, USA.
Joseph R G RinkaDepartment of Pharmacy, Froedtert and the Medical College of Wisconsin, Milwaukee; Department of Pharmacy Practice, Concordia University Wisconsin School of Pharmacy, Mequon, Wisconsin, USA.
Lisa M Baumann KreuzigerDepartment of Medicine, Division of Hematology and Oncology, Medical College of Wisconsin; The Blood Center of Wisconsin, Blood Research Institute, Milwaukee, Wisconsin, USA.
Paul S PagelDepartment of Anesthesiology, Medical College of Wisconsin; Clement J. Zablocki Veterans Affairs Medical Center, Milwaukee, Wisconsin, USA.
Justin N TawilDepartment of Anesthesiology, Medical College of Wisconsin, Milwaukee, Wisconsin, USA.
Medical College of Wisconsin · USFroedtert Hospital · USConcordia University Wisconsin · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Excessive bleeding and surgical reexploration are common complications that increase the risk of multi-organ failure and prolonged hospitalization after cardiac surgery. Off-label use of recombinant activated factor VII (rFVIIa) is a recommended treatment for refractory bleeding. Objective: The objective of the study is to determine if the adequacy of hemostatic resuscitation enhances the efficacy of rFVIIa. Methods: This retrospective, observational, cohort study included patients who received rFVIIa for refractory postoperative bleeding after cardiac surgery. Patients were divided into two groups based on the presence or absence of adequate coagulation resuscitation before rFVIIa administration, defined as international ratio (INR) ≤1.5, platelet count ≥100 K/mL, and fibrinogen ≥200 mg/dL. The failure of rFVIIa treatment was defined as surgical reexploration within 24 h, thoracostomy drainage >400 mL/h within 6 h or transfusion of additional blood products or another rFVIIa dose within 6 h after initial rFVIIa dose. Results: Of the 3833 patients, screened who underwent cardiothoracic surgery procedures, 58 patients received rFVIIa for refractory postoperative bleeding. Successful hemostasis with rFVIIa was more likely in patients who were adequately resuscitated compared with those who were not (20 [71.4%] vs. 10 [33.3%], respectively; P = 0.0046). Multiple logistic regression analysis indicated that patients who were adequately resuscitated before rFVIIa were less likely to fail treatment (odds ratio, 0.16; 95% confidence interval [0.04-0.62]; P = 0.007). Conclusions: The therapeutic efficacy of rFVIIa is dependent on the adequacy of hemostatic resuscitation; restoration of normal serum fibrinogen, INR, and platelet counts >100 K/mL may provide an adequate substrate for rFVIIa to be effective in managing refractory postoperative cardiac surgical bleeding.

Indexed as

Blood Loss, SurgicalHemostasisAgedAged, 80 and overCardiac Surgical ProceduresCohort StudiesFactor VIIaFemaleHemostaticsHumansMaleMiddle AgedPostoperative HemorrhageRecombinant ProteinsReoperationResuscitationFactor VIIaHemostaticsrecombinant FVIIaRecombinant ProteinsCardiac surgerycoagulopathyhemostasispostoperative bleedingrecombinant activated factor VIItransfusion

Identifiers

PMID31621674
PMCPMC6813715
OpenAlexW2978485330

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.